Khi sức mạnh tính toán của AI cũng bắt đầu được "chia sẻ", ai sẽ trở thành người dẫn đầu trong cuộc cạnh tranh mới này?

Biolidics

company

About

Biolidics is focused on the development of medical devices to improve cancer diagnostics and patient care.

  • Singapore,Central Region,Singapore
  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
S$8.66M
Industries
Biotechnology,Health Care,Health Diagnostics
Founded date
Jan 1, 2009
Number Of Employee
11 - 50
Operating Status
Active
Legal Name
Clearbridge BioMedics Pte Ltd
Also Known As
Clearbridge Biomedics

Biolidics is a medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
S$15.26M
Biolidics has raised a total of S$15.26M in funding over 2 rounds. Their latest funding was raised on Jun 28, 2018 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 28, 2018 Series Unknown S$6.60M Detail
Mar 13, 2013 Series B S$8.66M 6 Vertex Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
6
Biolidics is funded by 6 investors. Vertex Ventures and Dark Horse Investment are the most recent investors.
Investor Name Lead Investor Funding Round
Vertex Ventures Yes Series B
Dark Horse Investment Series B
BioVeda Capital Series B
NUS Technology Holdings Series B
Spring SEEDS Capital Series B
Vertex Ventures Southeast Asia & India Series B

Employee Profiles

Number of Employee Profiles
4
Biolidics has 4 current employee profiles, including Board member Joo Hock Chua
Board member
Executive
Executive
Executive

Acquisition

Biolidics has acquired 1 organizations. Their most recent acquisition was Biomedical Laboratory on Mar 30, 2020. They acquired Biomedical Laboratory for $2.60M.

Date Company Name
Industry Acquisition Type Price
Genetics acquisition $ 2.60M Detail